Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18759408 | 0.94 | MAPT (0.43) | MAPTTDP2KDRAURKBABL1 | |
| SCHEMBL16046591 | 0.88 | DYRK1A (0.43) | MAPK14 | |
| SCHEMBL16045693 | 0.87 | GABRA1 (0.47) | MAPTGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL16044322 | 0.87 | GABRA1 (0.47) | MAPTGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL16045913 | 0.87 | SRC (0.42) | MAPTTDP2KDRAURKBABL1 | |
| SCHEMBL16044197 | 0.86 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL18759422 | 0.86 | PDE10A (0.37) | MAPTKDRAURKBBTKGABRA1 | |
| SCHEMBL18759413 | 0.86 | PDE10A (0.37) | MAPTKDRAURKBBTKGABRA1 | |
| Trifluoroacetic Acid SCHEMBL16045030 | 0.85 | COMT (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL16044266 | 0.84 | MAPK14 (0.50) | KDRGABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | disclosed |
| CN-105358561-A | Novel inhibitor compounds of phosphodiesterase type 10a | ABBVIE DEUTSCHLAND | 2016-02-24 | — | — | CN | disclosed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | disclosed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | MAPT 837/4885TDP2 49/4885KDR 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.